Abstract
In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594.
| Original language | English (US) |
|---|---|
| Journal | Leukemia and Lymphoma |
| DOIs | |
| State | Published - Jan 1 2019 |
| Externally published | Yes |
Fingerprint
Keywords
- Classical Hodgkin lymphoma
- health-related quality-of-life
- KEYNOTE-087
- patient-reported outcomes
- pembrolizumab
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. / von Tresckow, Bastian; Fanale, Michelle; Ardeshna, Kirit M.; Chen, Robert; Meissner, Julia; Morschhauser, Franck; Moskowitz, Craig; Zinzani, Pier Luigi; Giezek, Hilde; Balakumaran, Arun; Vo, Thao T.; Raut, Monika; Brice, Pauline.
In: Leukemia and Lymphoma, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
AU - von Tresckow, Bastian
AU - Fanale, Michelle
AU - Ardeshna, Kirit M.
AU - Chen, Robert
AU - Meissner, Julia
AU - Morschhauser, Franck
AU - Moskowitz, Craig
AU - Zinzani, Pier Luigi
AU - Giezek, Hilde
AU - Balakumaran, Arun
AU - Vo, Thao T.
AU - Raut, Monika
AU - Brice, Pauline
PY - 2019/1/1
Y1 - 2019/1/1
N2 - In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594.
AB - In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594.
KW - Classical Hodgkin lymphoma
KW - health-related quality-of-life
KW - KEYNOTE-087
KW - patient-reported outcomes
KW - pembrolizumab
UR - http://www.scopus.com/inward/record.url?scp=85064761416&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064761416&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1602262
DO - 10.1080/10428194.2019.1602262
M3 - Article
C2 - 31012356
AN - SCOPUS:85064761416
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
ER -